FDA Issues Warning Letters Against Online GLP 1 Sellers BioSpace FDA mulls compounding for peptides previously flagged over safety risks BioSpace The FDA has sent 30 warning letters to telehealth companies for falsely marketing compounded GLP 1s, which are not FDA approved and can pose risks to patients. FULL STORY:https: tinyurl.com 3ztf9uj2 The Human Lab Rats Injecting Themselves with Peptides Office for Science and Society McGill University Regulatory Alert: FDA's April 2026 Update on BPC 157 and GHK Cu Holt Law The U.S. Food and Drug Administration is moving toward allowing compounding pharmacies to produce more than a dozen injectable peptides that were banned because of potentially significant safety risks, the New York